Massimo Calafiore Sells 9,600 Shares of Orthofix Medical (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,600 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $15.82, for a total value of $151,872.00. Following the completion of the sale, the chief executive officer directly owned 227,034 shares of the company’s stock, valued at $3,591,677.88. This trade represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Massimo Calafiore also recently made the following trade(s):

• On Monday, January 12th, Massimo Calafiore sold 9,797 shares of Orthofix Medical stock. The shares were sold at an average price of $15.21, for a total value of $149,012.37.

Orthofix Medical Trading Down 3.3%

OFIX opened at $14.32 on Thursday. Orthofix Medical Inc. has a 52 week low of $10.24 and a 52 week high of $20.48. The company has a quick ratio of 1.38, a current ratio of 2.47 and a debt-to-equity ratio of 0.39. The business has a fifty day simple moving average of $15.38 and a 200-day simple moving average of $14.26. The firm has a market cap of $567.07 million, a P/E ratio of -4.73 and a beta of 0.79.

Wall Street Analyst Weigh In

OFIX has been the subject of a number of research reports. Barrington Research lifted their price objective on shares of Orthofix Medical from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Stifel Nicolaus assumed coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They set a “buy” rating and a $22.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.50.

Institutional Trading of Orthofix Medical

Hedge funds have recently added to or reduced their stakes in the company. CWM LLC grew its holdings in Orthofix Medical by 99.0% during the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock worth $28,000 after acquiring an additional 955 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of Orthofix Medical during the 3rd quarter worth $30,000. Strs Ohio purchased a new stake in shares of Orthofix Medical during the 1st quarter worth $150,000. Mackenzie Financial Corp acquired a new position in shares of Orthofix Medical during the third quarter worth $148,000. Finally, Diversified Trust Co. purchased a new position in Orthofix Medical in the fourth quarter valued at $159,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.